Abbott Laboratories fell on its latest earnings report, but I view this as a buying opportunity. Read the latest analysis on ...

Healthcare product and device company Abbott Laboratories (NYSE:ABT) fell short of the markets revenue expectations in Q4 ...

Shares of Abbott Laboratories plunged 10.04% to $108.61 Thursday, on what proved to be an all-around great trading session ...

Abbott shares fell after quarterly sales and early 2026 earnings guidance missed estimates, even as the company forecast ...

The medical-products maker’s shares tumbled after its quarterly profit and sales underwhelmed investors.

Abbott Laboratories reported Q4 2025 sales of $11.46 billion, an increase of 4.4% from the previous year but falling short of analyst projections by approximately 3%. The adjusted EPS was $1.50, ...

Abbott Laboratories saw its shares down 10% at the end of trading Thursday, Jan. 22, as the market digested weaknesses from its fourth-quarter and full-year earnings report. | Abbott Laboratories saw ...

Abbott received CE Mark for the TactiFlex™ Duo Ablation Catheter to treat patients with abnormal heart rhythms. Shares of Abbott fell 0.3% to close at $120.73 on Wed ...

Abbott Laboratories ( ABT) Q4 2025 Earnings Call January 22, 2026 9:00 AM EST Good morning, and thank you for standing by.

Abbott shares sank 8% as Q4 revenue of $11.5B missed the $11.8B target, with nutrition sales dropping 8.9% on price ...

Despite facing headwinds, Abbott Laboratories (ABT) reports robust earnings growth and outlines plans for innovation and ...

By Saurabh Sharma and Arpan Chaturvedi GHAZIABAD, India, Jan 23 (Reuters) - Indian drugmaker Abbott Healthcare's supply chain is being scrutinised as part of a wider investigation into the alleged ...